Current Opinion for Hypertension in Renal Fibrosis.

Current Opinion for Hypertension in Renal Fibrosis. Adv Exp Med Biol. 2019;1165:37-47 Authors: Sun HJ Abstract Arterial hypertension remains to be a serious problem with considerable morbidity and mortality worldwide in the present age. Hypertension is a major risk factor for cardiovascular diseases such as stroke, myocardial infarction, renal failure, and heart failure. Hypertensive nephropathy is the second leading cause of death in chronic kidney disease (CKD) around the world. Long-time hypertension loading results in renal interstitial fibrosis, which is associated with aberrant activation of renal fibroblasts and excessive generation of extracellular matrix (ECM) proteins. Increasing evidence supported that proteinuria, tubular hypertrophy, oxidative stress, activation of renin-aldosterone-angiotensin system (RAAS), collagen turnover, chronic inflammation, and vasoactive substances synergistically contributed to the pathogenesis of hypertensive renal fibrosis. However, the mechanisms involving the pathogenesis of hypertensive renal fibrosis are complex and not fully understood. Also, the effective clinical therapy to halt or even reverse renal fibrosis in hypertension is still limited. In this chapter, we aimed to provide an overview of the main pathophysiologic and mechanistic features of renal fibrosis under hypertensive state. The completion of the studies in these directions would improve our understanding of renal fibrosis in hypertension and a...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research

Related Links:

I know its not recommended, but any people here with experience?
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Anesthesiology Source Type: forums
U.K. researchers are offering an outline of neurological manifestations of...Read more on AuntMinnie.comRelated Reading: Kids with SARS-CoV-2 may develop second inflammation MRI shows 8 neuroradiologic patterns of COVID-19 MRI tracks brain damage caused by COVID-19 COVID-19 neuro findings marked by mental status, stroke MRI illuminates neurologic manifestations of COVID-19
Source: Headlines - Category: Radiology Source Type: news
Authors: Kruska M, Fastner C, Scheitz JF, Kolb A, Rutsch M, Papavassiliu T, Borggrefe M, Alonso A, Akin I, Szabo K, Baumann S Abstract Routine determination of troponin levels is recommended for all patients with acute ischemic stroke. In 20-55% of these patients the troponin levels are elevated, which may be caused by ischemic as well as non-ischemic myocardial damage and particularly neurocardiogenic myocardial damage. In patients with acute ischemic stroke, the prevalence of previously unknown coronary heart disease is reported to be up to 27% and is prognostically relevant for these patients; however, relevant ...
Source: Herz - Category: Cardiology Tags: Herz Source Type: research
Authors: Karataş MB, Çanga Y, Yelgeç NS, Zengin A, Güzelburç Ö, Eren S, Emre A Abstract BACKGROUND: Digoxin treatment has come under scrutiny in recent years after reports from several studies that it is associated with increased mortality in patients with atrial fibrillation (AF). The clinical effects of digoxin on mortality were closely related to serum digoxin concentrations (SDC) in these studies. In the present work, we evaluated the role of the SAMe-TT2R2 and modified SAMe-TT2R2 scores in predicting the therapeutic range of digoxin therapy. METHODS: Medical records from our...
Source: Herz - Category: Cardiology Tags: Herz Source Type: research
CONCLUSION: In patients that underwent P‑PCI for the treatment for STEMI, LVEF, LAVI, PAP and creatinine level independently predicted all-cause mortality and new onset HF during long-term follow-up. PMID: 32632548 [PubMed - as supplied by publisher]
Source: Herz - Category: Cardiology Tags: Herz Source Type: research
Authors: Gunawardene MA, Hartmann J, Jularic M, Eickholt C, Gessler N, Willems S Abstract Atrial fibrillation (AF) is the most frequent persistent cardiac arrhythmia and is associated with an increased mortality. Therefore, an effective differential treatment of patients is mandatory. After a risk stratification oral anticoagulation (OAC) should be initiated depending on the individual stroke risk of each patient. Alternatively, in the presence of contraindications for OAC and an increased risk for bleeding and/or stroke, the implantation of a left atrial appendage closure device can be considered. Symptomatic pati...
Source: Herz - Category: Cardiology Tags: Herz Source Type: research
Authors: Deltour S, Pautas E Abstract Primary and secondary prevention of stroke is often a challenge in elderly patients due to the increase in both thrombotic and hemorrhagic risks with age. In some cases, there is sufficient data in the elderly population to allow recommendations or anticoagulation decisions to be made, such as for the indication of anticoagulation to prevent stroke related to atrial fibrillation (AF) or the choice of oral anticoagulant therapy in this situation. In other situations, the less robust data leave some questions; this is the case for the delay to initiate an oral anticoagulant thera...
Source: Revue Neurologique - Category: Neurology Tags: Rev Neurol (Paris) Source Type: research
Authors: Hojo T, Shibuya M, Kimura Y, Otsuka Y, Fujisawa T Abstract Angiotensin receptor blockers (ARBs) are commonly used to treat hypertension. However, similar to angiotensin-converting enzyme inhibitors, ARBs can also cause refractory hypotension during general anesthesia. Therefore, it has been recommended that ARBs be withheld for 24 hours prior to the induction of anesthesia. This is a case report of refractory hypotension requiring the administration of potent vasopressors after the induction of general anesthesia despite withholding telmisartan for 24 hours. In the same patient undergoing a subsequent gene...
Source: Anesthesia Progress - Category: Anesthesiology Tags: Anesth Prog Source Type: research
Authors: Dworakowska D, Grossman AB Abstract COVID-19, which is caused by the single-stranded RNA severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has introduced significant therapeutic dilemmas in several areas. One of these is concern regarding the use of renin-angiotensin system (RAS) inhibitors. Dysfunction of the RAS has been observed in COVID-19 patients, but whether RAS inhibitors, such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type-1 receptor blockers (ARBs), are associated with improved or worse clinical outcomes, remains unclear. RAS inhibitors are currently widel...
Source: Journal of Physiology and Pharmacology - Category: Drugs & Pharmacology Tags: J Physiol Pharmacol Source Type: research
Publication date: 7 July 2020Source: Cell Reports, Volume 32, Issue 1Author(s): Min-Ho Nam, Jongwook Cho, Dae-Hyuk Kwon, Ji-Young Park, Junsung Woo, Jungmoo Lee, Sangwon Lee, Hae Young Ko, Woojin Won, Ra Gyung Kim, Hanlim Song, Soo-Jin Oh, Ji Won Choi, Ki Duk Park, Eun Kyung Park, Haejin Jung, Hyung-Seok Kim, Min-Cheol Lee, Mijin Yun, C. Justin Lee
Source: Cell Reports - Category: Cytology Source Type: research
More News: Biology | Cardiology | Cardiovascular | Chronic Kidney Disease | Heart | Heart Attack | Heart Failure | Hypertension | Proteinuria | Renal Failure | Research | Stroke | Study | Urology & Nephrology